Development of a vesivas immunosimilar formulation
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93021C00039
- Awardee
-
Molecular Express, Inc. UEI R1JMHFESEKD5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $569,807
Award facts
- Opportunity
-
- PHS202101 Solicitation number
- Contract value 100% obligated
- $569,807.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 3 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- CRYSTAL CITY, CA 90220, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $569,807 |
About this award
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $569,807 definitive contract to Molecular Express Inc. to support the development of a vesivis immunosimilar formulation. The firm fixed price contract runs from August 2021 through July 2023 and will be performed in Crystal City, California. Designated as a total small business set aside, the award tasks Molecular Express with delivering products and services to advance the NIH's research into developing biosimilar treatments for allergies and infectious diseases. Key aspects of the original solicitation likely involved requesting proposals for formulations similar to existing immunotherapies.
Quick answers
Who was awarded contract 75N93021C00039?
75N93021C00039 was awarded to Molecular Express, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 1, 2021.
How much is contract 75N93021C00039 worth?
The government has obligated $569,807 on 75N93021C00039.
Was contract 75N93021C00039 competed?
The extent of competition for 75N93021C00039 was full and open competition after exclusion of sources. The government received 3 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award